The ALS therapy candidate AP-101 significantly extended patient survival and delayed the need for respiratory support in a ...

ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery - current cell models used for ...

The PREVAiLS study will be conducted at up to 60 ALS centres throughout 13 countries.

ALS is a heterogeneous disease. While 10-15% of cases are linked to inherited mutations, nearly 85% are sporadic.

A new gene therapy, Celosia's CTx1000, is now being tested for ALS in a small clinical trial in Australia. The one-time treatment targets toxic TDP-43 protein clumps, a key driver of most cases of ALS ...

In a phase 2b clinical trial, an investigational oral therapy called PrimeC was found to be safe and well tolerated in people ...

NeuroSense's Breakthrough ALS Combination Therapy PrimeC Has Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target ...

BREMERTON, WA / ACCESS Newswire / July 7, 2025 / On July 4, 1939, Lou Gehrig delivered his iconic “luckiest man” speech, announcing his retirement from the New York Yankees. On that day, ALS ended his ...

The MarketWatch News Department was not involved in the creation of this content. State-of-the-art remote-participation research seeks to understand how genetic factors linked to intense activities ...